Trial reportJAMA network open2023
Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial.
Trial report in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03522259 (BARIVA), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-Analysis on the Use of Rivaroxaban as Thromboprophylaxis Following Bariatric Surgery.Obesity surgery · 2026Pooled it
- Extended Venous Thromboembolism Prophylaxis After One-Anastomosis Gastric Bypass: A Three-Arm Randomized Trial of Enoxaparin Duration and Rivaroxaban.Obesity surgery · 2026Trial
- Early and Late Complications After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Narrative Review.Journal of metabolic and bariatric surgery · 2026Review
- A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery.Research and practice in thrombosis and haemostasis · 2026Review
- Post-discharge VTE prophylaxis after bariatric surgery: balancing bleeding risk and thrombosis prevention in 275,843 patients.Surgical endoscopy · 2026Article
- Prediction of venous thromboembolism after metabolic and bariatric surgery using machine learning approach: a MBSAQIP study.Surgical endoscopy · 2026Article
- Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety.Frontiers in pharmacology · 2026Article
- Thromboembolic prophylaxis in bariatric and metabolic surgery: state-of-the-art according to the results of a nationwide registry study.Updates in surgery · 2025Article
- Obesity and Venous Thromboembolism: Mechanisms, Clinical Implications, and Prevention Strategies With a Focus on Bariatric Surgery.Journal of metabolic and bariatric surgery · 2025Review
- Hematologists' comfort and experiences with providing care to transgender youth.Blood vessels, thrombosis & hemostasis · 2025Article
- Perioperative Outcomes in Patients with and Without Chronic Preoperative Therapeutic Anticoagulation Undergoing Metabolic Surgery at an Academic Medical Center.Journal of clinical medicine · 2025Article
- Dose Optimization of Rivaroxaban in Elderly Chinese Patients with Non-Valvular Atrial Fibrillation: Analysis of Populations Pharmacokinetics and Exposure-Response Relationships.Drug design, development and therapy · 2025Observational
- Thrombotic complications following bariatric surgery: how medical tourism poses challenges to comprehensive care in obesity medicine.Clinical journal of gastroenterology · 2024Article
- Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China.Liver research (Beijing, China) · 2024Article
- Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease.Nature reviews. Cardiology · 2024Review
- Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use.Research and practice in thrombosis and haemostasis · 2024Article
- Challenges in the care and treatment of patients with extreme obesity.Archives of endocrinology and metabolism · 2024Review
- Anticoagulation approach in morbid obesity: a comprehensive review on venous thromboembolism management.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality after bariatric surgery. Clinical end point studies on thromboprophylaxis with direct oral anticoagulants in patients undergoing bariatric surgery are lacking. Objective: To assess the efficacy and safety of a prophylactic dose of 10 mg/d of rivaroxaban for both 7 and 28 days after bariatric surgery. Design, Setting, and Participants: This assessor-blinded, phase 2, multicenter randomized clinical trial was conducted from July 1, 2018, through June 30, 2021, with participants from 3 academic and nonacademic hospitals in Switzerland. Intervention: Patients were randomized 1 day after bariatric surgery to 10 mg of oral rivaroxaban for either 7 days (short prophylaxis) or 28 days (long prophylaxis). Main Outcomes and Measures: The primary efficacy outcome was the composite of deep vein thrombosis (symptomatic or asymptomatic) and pulmonary embolism within 28 days after bariatric surgery. Main safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and mortality. Results: Of 300 patients, 272 (mean [SD] age, 40.0 [12.1] years; 216 women [80.3%]; mean body mass index, 42.2) were randomized; 134 received a 7-day and 135 a 28-day VTE prophylaxis course with rivaroxaban. Only 1 thromboembolic event (0.4%) occurred (asymptomatic thrombosis in a patient undergoing sleeve gastrectomy with extended prophylaxis). Major or clinically relevant nonmajor bleeding events were observed in 5 patients (1.9%): 2 in the short prophylaxis group and 3 in the long prophylaxis group. Clinically nonsignificant bleeding events were observed in 10 patients (3.7%): 3 in the short prophylaxis arm and 7 in the long prophylaxis arm. Conclusions and Relevance: In this randomized clinical trial, once-daily VTE prophylaxis with 10 mg of rivaroxaban was effective and safe in the early postoperative phase after bariatric surgery in both the short and long prophylaxis groups. Trial Registration: ClinicalTrials.gov Identifier: NCT03522259.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.